We are developing best-in-class ultra-long-acting medicines for chronic viral infections and CNS disorders, where better adherence and compliance can dramatically improve patient outcomes.OUR APPROACH
Exavir prodrug nano-formulation technology can prolong the apparent half-life of small molecule drugs by >100X.
Estimated infections in the US
Estimated infections worldwide
Annual drug sales in HIV category
Increase in healthcare costs for HIV+ vs HIV-
Patients are fully adherent to treatment
Prefer long-acting therapy to daily oral therapy
Risk-reduction when HIV PrEP is taken as prescribed
Exavir’s small molecule platform technology enables ultra-long-acting release for potentially once-every-six-months and longer dosing
MU OPIOID RECEPTOR
MUSCARINIC M4 RECEPTOR
Exavir's aqueous nanocrystal suspension technology can deliver small molecules to specific target tissues.
Exavir's decorated lipid nanoparticle technology can deliver nucleic acid cargo to specific target cell populations.
EXAVIR LIPID NANOPARTICLESRead More